DAFTAR PUSTAKA

AbuAlrob, M.A. and Tadi, P. (2023) *Neuroanatomy, Nucleus Solitarius*, *2023 jan*. Available at: https://www.ncbi.nlm.nih.gov/books/NBK549831/ (Accessed: 6 October 2023).

Agustini, N., Setiawan, A. and Salni, S. (2020) 'Effect Of Pomegranate (Punica granatum L.) Fraction In Reducing Total Blood Cholesterol Levels and Triglyceride in Mice (Mus muscullus L.)', *Indonesian Journal of Environmental Management and Sustainability*, 4(1), pp. 14–22. Available at: https://doi.org/10.26554/ijems.2020.4.1.14-22.

Akbarpour, M. *et al.* (2021) 'O riginal Article Effects of Eight Weeks of Resistance Training and Consumption of Pomegranate on GLP-1 , DPP-4 and Glycemic Statuses in Women with Type 2 Diabetes : A Randomized Controlled Trial', 8(1), pp. 5–10.

Amri, Z. *et al.* (2017) 'Effect of pomegranate extracts on brain antioxidant markers and cholinesterase activity in high fat-high fructose diet induced obesity in rat model', *BMC Complementary and Alternative Medicine*, 17(1), pp. 1–9. Available at: https://doi.org/10.1186/s12906-017-1842-9.

Amri, Z. *et al.* (2020) 'Anti-diabetic effects of pomegranate extracts in long-term high fructose-fat fed rats', *Clinical Phytoscience*, 6(55), pp. 1–9.

Aviram, M. and Rosenblat, M. (2013) 'Pomegranate for Your Cardiovascular Health', *Rambam Maimonides Medical Journal*, 4(2), p. e0013. Available at: https://doi.org/10.5041/rmmj.10113.

Bhatti, M.S., Akbri, M.Z. and Shakoor, M. (2001) 'Lipid profile in obesity.', *Journal of dical College, Abbottabad : JAMC*, 13(1), pp. 31–33.

).S. *et al.* (2022) 'Potential Mechanisms of the Improvement of Glucose asis in Type 2 Diabetes by Pomegranate Juice', *Antioxidants*, 11(3), pp. 1–

13. Available at: https://doi.org/10.3390/antiox11030553.

Catenacci, V.A., Hill, J.O. and Wyatt, H.R. (2009) 'The Obesity Epidemic', *Clinics in Chest Medicine*, 30(3), pp. 415–444. Available at: https://doi.org/10.1016/j.ccm.2009.05.001.

Cheurfa, M. *et al.* (2020) 'Antioxidant and anti-diabetic activity of pomegranate (Punica granatum L.) leaves extracts', *Foods and Raw Materials*, 8(2), pp. 329–336. Available at: https://doi.org/10.21603/2308-4057-2020-2-329-336.

Chooi, Y.C., Ding, C. and Magkos, F. (2019) 'The epidemiology of obesity', *Metabolism: Clinical and Experimental*, 92, pp. 6–10. Available at: https://doi.org/10.1016/j.metabol.2018.09.005.

Cunningham, J.W. and Wiviott, S.D. (2014) 'Modern obesity pharmacotherapy: Weighing cardiovascular risk and benefit', *Clinical Cardiology*, 37(11), pp. 693–699. Available at: https://doi.org/10.1002/clc.22304.

Das, S. and Barman, S. (2012) 'Antidiabetic and antihyperlipidemic effects of ethanolic extract of leaves of Punica granatum in alloxan-induced non-insulin-dependent diabetes mellitus albino rats', *Indian Journal of Pharmacology*, 44(2), pp. 219–224. Available at: https://doi.org/10.4103/0253-7613.93853.

Engin, A. (2017) 'The Definition and Prevalence of Obesity and Metabolic Syndrome', in, pp. 1–17. Available at: https://doi.org/10.1007/978-3-319-48382-5_1.

Gabery, S. *et al.* (2020) 'Semaglutide lowers body weight in rodents via distributed neural pathways', *JCI Insight*, 5(6), pp. 1–18. Available at: https://doi.org/10.1172/jci.insight.133429.

Hall, J.E. and Guyton, A.C. (2016) *Guyton and Hall of Medical Physiology*. Thirteenth, *f Chemical Information and Modeling*. Thirteenth. Elsevier.

Isaacs, D. and Clements, J.N. (2018) 'Pharmacokinetics and Clinical

Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist', *Clinical Pharmacokinetics*, 57(12), pp. 1529–1538. Available at: https://doi.org/10.1007/s40262-018-0668-z.

Kalra, S. and Sahay, R. (2020) 'A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus', *Diabetes Therapy*, 11(9), pp. 1965–1982. Available at: https://doi.org/10.1007/s13300-020-00894-y.

Kosnayani, A.S. *et al.* (2021) 'Pengaruh Kombinasi Metformin dan Ekstrak Air Meniran (Phyllanthus Niruri Linn.) terhadap Perbaikan Status Obesitas Tikus Sprague Dawley Jantan Effect Combination of Metformin and Meniran (Phyllanthus niruri Linn.) Water Extract on the Improvement of Obesi', *Amerta Nutrition*, 5, pp. 52–58. Available at: https://doi.org/10.20473/amnt.v5i1.2021.

Ladenheim, E.E. (2015) 'Liraglutide and obesity: A review of the data so far', *Drug Design, Development and Therapy*, 9(2015), pp. 1867–1875. Available at: https://doi.org/10.2147/DDDT.S58459.

Lei, F. *et al.* (2007) 'Evidence of anti-obesity effects of the pomegranate leaf extract in high-fat diet induced obese mice', *International Journal of Obesity*, 31(6), pp. 1023–1029. Available at: https://doi.org/10.1038/sj.ijo.0803502.

Les, F. *et al.* (2018) 'Pomegranate polyphenols and urolithin A inhibit α-glucosidase, dipeptidyl.pdf'. Available at: https://doi.org/https://doi.org/10.1016/j.jep.2018.03.029.

Liu, D. *et al.* (2022) 'Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice', *Canadian Journal of Diabetes*, 46(3), pp. 216-224.e2. Available at: https://doi.org/10.1016/j.jcjd.2021.08.012.

N. *et al.* (2022) 'Medicinal uses, pharmacological activities, phytochemistry, nolecular mechanisms of Punica granatum L. (pomegranate) plant extracts: ', *Biomedicine and Pharmacotherapy*, 153(July), p. 113256. Available at: i.org/10.1016/j.biopha.2022.113256.

Meloni, A.R. *et al.* (2013) 'GLP-1 receptor activated insulin secretion from pancreatic β-cells: Mechanism and glucose dependence', *Diabetes, Obesity and Metabolism*, pp. 15–27. Available at: https://doi.org/10.1111/j.1463-1326.2012.01663.x.

Negi, H. *et al.* (2021) 'Medicinal Plants and Natural Products: More Effective and Safer Pharmacological Treatment for the Management of Obesity', *Current Drug Metabolism*, 22(12), pp. 918–930. Available at: https://doi.org/10.2174/1389200222666210729114456.

Novelli, E.L.B. *et al.* (2007) 'Anthropometrical parameters and markers of obesity in rats', *Laboratory Animals*, 41(1), pp. 111–119. Available at: https://doi.org/10.1258/002367707779399518.

Pan, X. *et al.* (2022) 'Effects of Semaglutide on Cardiac Protein Expression and Cardiac Function of Obese Mice', *Journal of Inflammation Research*, 15, pp. 6409–6425. Available at: https://doi.org/10.2147/JIR.S391859.

Salam, et al. (2023) 'Obesity and Overweight : A Global Public Health Issue', *Advances in Human Biology* |, (Feb,2,2023), pp. 2–3. Available at: https://doi.org/10.13140/RG.2.2.15819.26400.

Shabana, Shahid, S.U. and Sarwar, S. (2020) 'The abnormal lipid profile in obesity and coronary heart disease (CHD) in Pakistani subjects', *Lipids in Health and Disease*, 19(1), pp. 1–7. Available at: https://doi.org/10.1186/s12944-020-01248-0.

Sharma, D. *et al.* (2019) 'DPP-IV inhibitors from natural sources: An alternative approach for treatment and management of diabetes', *Indian Journal of Natural Products and Resources*, 10(4), pp. 227–237.

Suharti, B., Kartika, T. and Sugiyanta, S. (2021) 'Culture and social: herbal medicine ı communication to build urban community empowerment', *Jurnal Studi ɜsi (Indonesian Journal of Communications Studies)*, 5(1), p. 151. Available /doi.org/10.25139/jsk.v5i1.3124.

Thompson, W.G. *et al.* (2007) 'Treatment of obesity', *Mayo Clinic Proceedings*, 82(1), pp. 93–102. Available at: https://doi.org/10.4065/82.1.93.

Vendrell, J. *et al.* (2011) 'Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance', *Endocrinology*, 152(11), pp. 4072–4079. Available at: https://doi.org/10.1210/en.2011-1070.

WHO (2021) *Obesity and Overweight*. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (Accessed: 5 September 2023).

Wisse, B.E. and Schwartz, M.W. (2009) 'Does Hypothalamic Inflammation Cause Obesity?', *Cell Metabolism*, 10(4), pp. 241–242. Available at: https://doi.org/10.1016/j.cmet.2009.09.003.